Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon

Masao Arai, Maki Niioka, Katsuya Maruyama, Norihito Wada, Noboru Fujimoto, Tetsu Nomiyama, Shoutarou Tanaka, Isao Okazaki

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

We treated 18 patients with chronic hepatitis C by recombinant interferon-α (6 MIU for 24 weeks). In seven patients, serum aminotransferase levels declined to normal (responders). To evaluate the effect of interferon on matrix metalloproteinases (MMPs) and their inhibitors, namely tissue inhibitors of metalloproteinases (TIMPs), the serum levels of these enzymes were determined by enzyme immunoassay (EIA) using a specific monoclonal antibody. In responders, there was a tendency, but not a significant one, towards either an increase in serum MMP 1 levels or a decrease in serum TIMP 1 levels. In contrast, in nonresponders, both a significant decrease in MMP 1 and MMP 3 and a significant increase in TIMP 1 were observed. The number of cases of either increase in serum MMP levels or decrease in serum TIMP levels was significantly larger in responders than in nonresponders. Furthermore, the ratio of MMP 1 to TIMP 1 significantly increased in responders, suggesting that the balance between matrix formation and degradation in hepatic fibrosis tended to move toward degradation. These data indicate that interferon may exert a beneficial effect on hepatic fibrosis in parallel with improvement of aminotransferase activity.

Original languageEnglish
Pages (from-to)995-1000
Number of pages6
JournalDigestive Diseases and Sciences
Volume41
Issue number5
Publication statusPublished - 1996
Externally publishedYes

Fingerprint

Metalloproteases
Chronic Hepatitis C
Interferons
Matrix Metalloproteinase 1
Tissue Inhibitor of Metalloproteinase-1
Serum
Tissue Inhibitor of Metalloproteinases
Transaminases
Fibrosis
Therapeutics
Matrix Metalloproteinase 3
Matrix Metalloproteinase Inhibitors
Liver
Matrix Metalloproteinases
Immunoenzyme Techniques
Monoclonal Antibodies
Enzymes

Keywords

  • chronic hepatitis C
  • interferon
  • matrix metalloproteinases
  • tissue inhibitors of metalloproteinases

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Arai, M., Niioka, M., Maruyama, K., Wada, N., Fujimoto, N., Nomiyama, T., ... Okazaki, I. (1996). Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon. Digestive Diseases and Sciences, 41(5), 995-1000.

Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon. / Arai, Masao; Niioka, Maki; Maruyama, Katsuya; Wada, Norihito; Fujimoto, Noboru; Nomiyama, Tetsu; Tanaka, Shoutarou; Okazaki, Isao.

In: Digestive Diseases and Sciences, Vol. 41, No. 5, 1996, p. 995-1000.

Research output: Contribution to journalArticle

Arai, M, Niioka, M, Maruyama, K, Wada, N, Fujimoto, N, Nomiyama, T, Tanaka, S & Okazaki, I 1996, 'Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon', Digestive Diseases and Sciences, vol. 41, no. 5, pp. 995-1000.
Arai, Masao ; Niioka, Maki ; Maruyama, Katsuya ; Wada, Norihito ; Fujimoto, Noboru ; Nomiyama, Tetsu ; Tanaka, Shoutarou ; Okazaki, Isao. / Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon. In: Digestive Diseases and Sciences. 1996 ; Vol. 41, No. 5. pp. 995-1000.
@article{0a8886e6c2db490e9ef8e456838e626a,
title = "Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon",
abstract = "We treated 18 patients with chronic hepatitis C by recombinant interferon-α (6 MIU for 24 weeks). In seven patients, serum aminotransferase levels declined to normal (responders). To evaluate the effect of interferon on matrix metalloproteinases (MMPs) and their inhibitors, namely tissue inhibitors of metalloproteinases (TIMPs), the serum levels of these enzymes were determined by enzyme immunoassay (EIA) using a specific monoclonal antibody. In responders, there was a tendency, but not a significant one, towards either an increase in serum MMP 1 levels or a decrease in serum TIMP 1 levels. In contrast, in nonresponders, both a significant decrease in MMP 1 and MMP 3 and a significant increase in TIMP 1 were observed. The number of cases of either increase in serum MMP levels or decrease in serum TIMP levels was significantly larger in responders than in nonresponders. Furthermore, the ratio of MMP 1 to TIMP 1 significantly increased in responders, suggesting that the balance between matrix formation and degradation in hepatic fibrosis tended to move toward degradation. These data indicate that interferon may exert a beneficial effect on hepatic fibrosis in parallel with improvement of aminotransferase activity.",
keywords = "chronic hepatitis C, interferon, matrix metalloproteinases, tissue inhibitors of metalloproteinases",
author = "Masao Arai and Maki Niioka and Katsuya Maruyama and Norihito Wada and Noboru Fujimoto and Tetsu Nomiyama and Shoutarou Tanaka and Isao Okazaki",
year = "1996",
language = "English",
volume = "41",
pages = "995--1000",
journal = "American Journal of Digestive Diseases",
issn = "0002-9211",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon

AU - Arai, Masao

AU - Niioka, Maki

AU - Maruyama, Katsuya

AU - Wada, Norihito

AU - Fujimoto, Noboru

AU - Nomiyama, Tetsu

AU - Tanaka, Shoutarou

AU - Okazaki, Isao

PY - 1996

Y1 - 1996

N2 - We treated 18 patients with chronic hepatitis C by recombinant interferon-α (6 MIU for 24 weeks). In seven patients, serum aminotransferase levels declined to normal (responders). To evaluate the effect of interferon on matrix metalloproteinases (MMPs) and their inhibitors, namely tissue inhibitors of metalloproteinases (TIMPs), the serum levels of these enzymes were determined by enzyme immunoassay (EIA) using a specific monoclonal antibody. In responders, there was a tendency, but not a significant one, towards either an increase in serum MMP 1 levels or a decrease in serum TIMP 1 levels. In contrast, in nonresponders, both a significant decrease in MMP 1 and MMP 3 and a significant increase in TIMP 1 were observed. The number of cases of either increase in serum MMP levels or decrease in serum TIMP levels was significantly larger in responders than in nonresponders. Furthermore, the ratio of MMP 1 to TIMP 1 significantly increased in responders, suggesting that the balance between matrix formation and degradation in hepatic fibrosis tended to move toward degradation. These data indicate that interferon may exert a beneficial effect on hepatic fibrosis in parallel with improvement of aminotransferase activity.

AB - We treated 18 patients with chronic hepatitis C by recombinant interferon-α (6 MIU for 24 weeks). In seven patients, serum aminotransferase levels declined to normal (responders). To evaluate the effect of interferon on matrix metalloproteinases (MMPs) and their inhibitors, namely tissue inhibitors of metalloproteinases (TIMPs), the serum levels of these enzymes were determined by enzyme immunoassay (EIA) using a specific monoclonal antibody. In responders, there was a tendency, but not a significant one, towards either an increase in serum MMP 1 levels or a decrease in serum TIMP 1 levels. In contrast, in nonresponders, both a significant decrease in MMP 1 and MMP 3 and a significant increase in TIMP 1 were observed. The number of cases of either increase in serum MMP levels or decrease in serum TIMP levels was significantly larger in responders than in nonresponders. Furthermore, the ratio of MMP 1 to TIMP 1 significantly increased in responders, suggesting that the balance between matrix formation and degradation in hepatic fibrosis tended to move toward degradation. These data indicate that interferon may exert a beneficial effect on hepatic fibrosis in parallel with improvement of aminotransferase activity.

KW - chronic hepatitis C

KW - interferon

KW - matrix metalloproteinases

KW - tissue inhibitors of metalloproteinases

UR - http://www.scopus.com/inward/record.url?scp=0029996342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029996342&partnerID=8YFLogxK

M3 - Article

C2 - 8625775

AN - SCOPUS:0029996342

VL - 41

SP - 995

EP - 1000

JO - American Journal of Digestive Diseases

JF - American Journal of Digestive Diseases

SN - 0002-9211

IS - 5

ER -